90%Confidence
0Views
FDASource
2026-04-03Date
Summary
New Life Pharma's Class II FDA recall for Semaglutide injection due to sterility assurance issues presents significant patient safety concerns for this popular diabetes/weight loss medication. This regulatory action could damage the company's reputation and create market opportunities for competitors in the rapidly growing GLP-1 agonist market.
Actionable: Evaluate exposure to New Life Pharma and consider shifting to established semaglutide manufacturers with stronger quality control records.
AI Confidence: 90%
Data Points
firmNew Life Pharma LLC
classificationClass II
statusOngoing
distributionOH
productSemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now